Phase 4
N=25
Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis
Atopic Dermatitis
Bottom Line
View on ClinicalTrials.gov: NCT00693693 ↗Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcome: Primary: Adherence to Locoid — .55; .60; .50 percentage of days
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- hydrocortisone 17-butyrate 0.1% Cream preparation (Drug); hydrocortisone 17-butyrate 0.1% Ointment preparation (Drug); hydrocortisone 17-butyrate 0.1% Lipocream preparation (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Wake Forest University
- Primary completion
- Sep 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Adherence to Locoid |
.55; .60; .50 | — |
Summary
The purpose of this research study is to better understand adherence to Locoid when people use it to treat atopic dermatitis.
Eligibility Criteria
Inclusion Criteria
- Male or female ≥ 18 years of age.
- Subjects must have diagnosis of mild to moderate atopic dermatitis using IGA criteria. (2 or 3 on severity scale)
- Subjects must have >5% TBSA and 130 gm of cream in a 2 week period.
- Having facial or groin involvement of their disease.
- Pregnant women and women who are breast feeding are to be excluded. Women of child bearing potential will be allowed to participate in the study, and these subjects will be required to use at least one form of birth control.
Data sourced from ClinicalTrials.gov (NCT00693693). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.